The company's products include the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel powered by proprietary T2 Magnetic Resonance (T2MR) technology, with an active pipeline that includes products for detection of additional sepsis pathogens and tests for Lyme disease. The company is positioned in the rapid diagnostics market, addressing critical care needs in sepsis and fungal infection detection.
Cyborg Score Rationale
In 2023, T2 Biosystems' revenue declined 67.75% to $7.19 million from $22.31 million, with net losses of $50.08 million. The company has negative shareholder equity of -$11.7 million and total debt of $11.9 million against total assets of $18.1 million. The company faces significant financial distress and operational headwinds.
Top Insights
Proprietary T2MR technology enables direct detection from unpurified samples, a differentiation advantage in diagnostics
Revenue collapsed 68% in 2023 and company operates at substantial loss, indicating commercialization challenges
Negative shareholder equity and high debt burden create existential financial risk
Pipeline includes adjacent markets (Lyme disease, additional sepsis markers) but execution risk remains high
Named Competitors
BACT ALERT — Blood culture and pathogen detection systems
PANBIO — Rapid diagnostic testing platforms
GeneXpert — Molecular diagnostic systems
Recent Developments
2023: Revenue declined to $7.19 million with net loss of $50.08 million
Listing on LSE (0A57) provides access to alternative capital markets
Active product development pipeline for expanded diagnostic applications
Open the full interactive T2 Biosystems, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.